PulmoCalc – AI Assistant for Pulmonologists

The description states that PulmoCalc is:

• An AI-powered platform
• Designed for pulmonologists
• Combines pulmonary education, clinical decision support, and interactive medical calculators
• Includes features such as:
  • Evidence-based pulmonary workflows
  • Interactive clinical calculators
  • Pneumonia severity assessment
  • Pulmonary embolism evaluation
  • Blood gas (ABG) interpretation
  • Pulmonary function test guidance
  • Sleep medicine tools
  • Educational learning modules
  • Rapid bedside clinical references

The platform is described as supporting physicians without replacing their clinical judgment.

Inference It appears to be a web-based application built using AI technologies, with a focus on integrating clinical knowledge and decision-making tools into one interface.

The author states:

• The product was inspired by the need for faster access to clinical resources during patient care.
• It aims to reduce workflow interruptions and cognitive load.
• It is positioned as an intelligent workspace that consolidates multiple sources of information.
• The platform is described as supporting physicians—not replacing their clinical judgment.

Inference The positioning evolved from a personal problem-solving effort into a broader vision for AI-assisted healthcare education and decision-making. The claim has shifted from a single-use tool to a potential ecosystem for physician learning and practice.

The description states:

• The primary users are pulmonologists.
• It is designed for physicians who need quick access to evidence-based pulmonary resources.
• The platform supports clinical decision-making in real-time, during bedside care.

Inference The target customer is a specific subset of healthcare professionals — pulmonologists — with an emphasis on those working in clinical settings where time and accuracy are critical.

Not evidenced.

The description does not mention:

• Revenue streams
• Pricing models
• Monetization strategy
• Customer acquisition or retention tactics

Inference No evidence of a defined business model or pricing structure exists in the provided information.

The description states:

• PulmoCalc was built using OpenAI technologies including ChatGPT, GPT-5.6, Codex, and ChatGPT Sites.
• AI was involved throughout the development process—from brainstorming to debugging.
• The platform includes hundreds of iterative improvements.
• It is a web application.

Inference The technical stack relies heavily on AI tools, particularly OpenAI’s offerings. Development appears to have been iterative and AI-assisted, suggesting a rapid prototyping approach.

Not evidenced.

The description does not contain:

• Customer data or usage metrics
• Revenue figures
• Number of users or active physicians
• Product adoption rates
• Feedback from end-users
• Market traction indicators

Inference There is no indication of product maturity or traction beyond the initial prototype and development phase.

Not evidenced.

The description does not mention:

• Competitors in the market
• Existing solutions for clinical decision support or pulmonary education
• Market share or competitive positioning
• Differentiation from other tools

Inference No evidence of competitive landscape analysis or awareness of existing players is present.

Key risks and red flags based on the description:

• Single-founder model: Only one team member (Dr. Ömer BAYARAM) is mentioned, raising questions about scalability and execution capacity.
• No revenue or traction evidence: The platform has not demonstrated any real-world usage or monetization.
• Unverified claims: All statements are self-reported and lack independent verification.
• AI dependency: Heavy reliance on OpenAI tools may pose risks related to availability, cost, or changes in API access.
• Clinical accuracy risk: Without clinical validation or user feedback, the safety and reliability of medical content cannot be assessed.

Inference The project lacks commercial viability signals and faces significant execution and trust risks due to its early-stage nature and lack of external validation.

1. What specific clinical workflows or decisions does PulmoCalc support, and how are these validated?
2. Have you conducted any usability testing with actual pulmonologists?
3. How do you plan to ensure ongoing scientific accuracy of the content?
4. Is there a roadmap for monetization or customer acquisition?
5. What is your strategy for scaling beyond the current single-founder model?
6. Are there any partnerships or pilot programs with hospitals or medical institutions?